Research programme: adenosine A2B receptor agonists - Bayer HealthCareAlternative Names: BAY 60-6583
Latest Information Update: 23 Mar 2010
At a glance
- Originator Bayer HealthCare
- Mechanism of Action Adenosine A2B receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Myocardial ischaemia
Most Recent Events
- 31 Mar 2007 Preclinical trials in Myocardial ischaemia in Germany (unspecified route)